




Amarin Corporation plc  
Investor Relations Department  
2 Pembroke House, Upper  
Pembroke  
Street 28-32  
Dublin 2  
Ireland

[Visit IR website](#)   
[Sign-up for Email alerts](#) 

**NASDAQ: AMRN**

Last Trade:	3.10
Trade Time:	2:43 PM ET May 21, 2018
Change:	-0.17  (-5.199%)
Day Range	3.08 - 3.30
52-Week Range	2.66 - 4.60
Volume	1,632,105

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.


## Company Profile

Amarin is conducting a cardiovascular outcomes study designed to evaluate the efficacy of Vascepa® in reducing cardiovascular events in a high-risk patient population on statin therapy called the REDUCE-IT trial.

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

- May 2, 2018*  
[Amarin Reports First Quarter 2018 Financial Results and Provides Update on Operations](#)
- Apr 26, 2018*  
[Amarin To Report First Quarter 2018 Results and Host Conference Call On May 2, 2018](#)
- Apr 23, 2018*  
[Amarin Announces Promotion of Aaron Berg to Position of Chief Commercial Officer](#)
- Apr 12, 2018*  
[Amarin Sponsors Three Scientific Presentations Scheduled for National Lipid Association Scientific Sessions](#)
- Apr 12, 2018*  
[Vascepa® \(Icosapent Ethyl\) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin-Treated Patients with Reduced Kidney Function and Persistent High Triglycerides](#)

### Financials [\[ View all \]](#)

- [First Quarter Financial Results](#)
- Feb 27, 2018*  
[Annual Report \(10-K\)](#)
- Apr 20, 2018*  
[Proxy Statement \(DEF 14A\)](#)
- May 2, 2018*  
[Quarterly Report \(10-Q\)](#)
- Nov 1, 2017*  
[Quarterly Report \(10-Q\)](#)
- Aug 2, 2017*  
[Quarterly Report \(10-Q\)](#)